CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...

The global clinical trials market is anticipated to grow at a CAGR of 6-7% from 2024 to 2029. This growth is driven by the ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

The review article titled"Current insights and future directions in Peyronie's disease management: A narrative review", was ...

Learn about the Montreal Chest Institute's redevelopment, merging history with innovation to enhance Quebec's life sciences ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE ...

A groundbreaking clinical trial on AI therapy chatbots shows significant reductions in depression, anxiety, and disordered ...